Morgan Stanley downgraded MorphoSys from Equal-Weight to Underweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | Overweight → Equal Weight | Wells Fargo | |
| 1/16/2024 | $9.19 → $10.40 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $3.70 → $9.19 | Underweight → Overweight | Morgan Stanley |
| 9/15/2023 | $3.50 → $9.25 | Sell → Neutral | Goldman |
| 7/17/2023 | Sell → Hold | Deutsche Bank | |
| 6/16/2023 | $3.30 → $10.00 | Underweight → Overweight | JP Morgan |
| 6/16/2023 | $17.00 | Overweight | Wells Fargo |
| 5/31/2023 | Buy | UBS |
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
SC 14D9/A - MorphoSys AG (0001340243) (Subject)
SC TO-T/A - MorphoSys AG (0001340243) (Subject)
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act").MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a resul
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the "Tak
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. MorphoSys (NASDAQ:MOR) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. icad (NASDAQ:ICAD) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. Renalytix (NAS
SC 13D/A - MorphoSys AG (0001340243) (Subject)
SC 13D/A - MorphoSys AG (0001340243) (Subject)
SC 13D/A - MorphoSys AG (0001340243) (Subject)
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis – Monjuvi® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth quarter of 2023 and US$ 92.0 million (€ 85.0 million) for the full year of 2023 – € 680.5 million in cash and other financial assets as of December 31, 2023 – MorphoSys to host conference call and webcast on Thursday, March 14, 2024, at 1:00 pm CET (12:00
Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the MorphoSys' website, www.morphosys.com.To join the conference call via pho
MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out"). The merger squeeze-out will become effective once the transfer resolution and merger have been registered in the commercial register of MorphoSys, and the merger has also been registered in the commercial register of Novarti
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a r
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the "T
Wells Fargo downgraded MorphoSys from Overweight to Equal Weight
Morgan Stanley downgraded MorphoSys from Overweight to Equal-Weight and set a new price target of $10.40 from $9.20 previously
Morgan Stanley upgraded MorphoSys from Underweight to Overweight and set a new price target of $9.20 from $3.70 previously
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally. Dr. Peltier has extensive global leadership and hands-on experiences in cl
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG ((FSE: MOR, NASDAQ:MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His successor will be Tim Demuth, M.D., Ph.D., current Chief Medical Officer of Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company. Tim will start his new role on October 1. He will report to MorphoSys' CEO, Jean-Paul Kress, M.D., and be a member of the company's Executive Committee. At this time, Malte will step down from his operational responsibili
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022, including:- The discharge of the members of the Management and Supervisory Boards with respect to the 2021 financial year- The appointment of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as auditor for the 2022 financial year- The election of Mr. Andrew Cheng, M.D., Ph.D., as Supervisory Board member- Resolution on the reduction of Conditional Capital 2016-III, Conditional Ca